Literature DB >> 26118878

[Advance in the biology of pancreatic of cancer].

Louis Buscail1, Barbara Bournet2, Marlène Dufresne2, Jérôme Torrisani2, Pierre Cordelier2.   

Abstract

The understanding of the biology of pancreatic carcinoma has greatly benefited from studies of genetic/epigenetic alterations and molecular expression in experimental models as well as precancerous and cancerous tissues by mean of molecular amplification and large-scale transcriptoma analysis. P16, TP53, DPC4/Smad4 tumor suppressor pathways are genetically inactivated in the majority of pancreatic carcinomas, whereas oncogenic k-ras is activated. The activating point mutation of the KRAS oncogene on codon 12 is the major event and occurs early in pancreatic carcinogenesis. At a late stage of tumor development, an increase of telomerase activity, an over expression of growth factors and/or their receptors (EGF, Nerve Growth Factor, gastrin), of pro-angiogenic factors (VEGF, FGF, PDGF), of invasiveness factors (metalloproteinases, tissue plasminogen activators) occurs. The microenvironment plays also a key role in the invasive and metastatic process of pancreatic carcinoma with a strong relationship between cancerous cells and pancreatic stellate cells as well as extracellular matrix. This microenvironment strongly participates to the tumor fibrosis, hypoxia and hypovascularization inducing an inaccessibility of drugs. Nowadays, the targeting of microenvironment takes a special place in the new therapeutic strategies of pancreatic cancer in combination with chemotherapy.
Copyright © 2015 Société Françise du Cancer. Publié par Elsevier Masson SAS. Tous droits réservés. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Cancer du pancréas; Cibles thérapeutiques; Epigenetics; Microenvironment; Microenvironnement; Molecular therapeutic; Moléculaires; Pancreatic ductal; adenocarcinoma; exocrine; targets; Épigénétique

Mesh:

Substances:

Year:  2015        PMID: 26118878     DOI: 10.1016/S0007-4551(15)31218-2

Source DB:  PubMed          Journal:  Bull Cancer        ISSN: 0007-4551            Impact factor:   1.276


  2 in total

1.  MIR210HG regulates glycolysis, cell proliferation, and metastasis of pancreatic cancer cells through miR-125b-5p/HK2/PKM2 axis.

Authors:  Tianzhu Yu; Guoping Li; Chenggang Wang; Gaoquan Gong; Liangwen Wang; Changyu Li; Yi Chen; Xiaolin Wang
Journal:  RNA Biol       Date:  2021-06-10       Impact factor: 4.766

2.  Apatinib concurrent gemcitabine for controlling malignant ascites in advanced pancreatic cancer patient: A case report.

Authors:  Lijun Liang; Lei Wang; Panrong Zhu; Youyou Xia; Yun Qiao; Kaiyuan Hui; Chenxi Hu; Yan Ren; Xiaodong Jiang
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.